CareDx, Inc (CDNA) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
CDNA Insider Trading Activity
CDNA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $6,098,174 | 16 | 100 |
Related Transactions
| Jain Abhishek | Chief Financial Officer | 0 | $0 | 1 | $4,696 | $-4,696 |
| Novack Jeffrey Adam | Secretary and General Counsel | 0 | $0 | 6 | $337,387 | $-337,387 |
| Bickerstaff George | director | 0 | $0 | 1 | $367,102 | $-367,102 |
| COURNOYER CHRISTINE | director | 0 | $0 | 2 | $700,951 | $-700,951 |
| Maag Peter | director | 0 | $0 | 3 | $1.53M | $-1.53M |
| Johnson Alexander L | See Remarks | 0 | $0 | 3 | $3.16M | $-3.16M |
About CareDx, Inc
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Insider Activity of CareDx, Inc
Over the last 12 months, insiders at CareDx, Inc have bought $0 and sold $6.1M worth of CareDx, Inc stock.
On average, over the past 5 years, insiders at CareDx, Inc have bought $240,266 and sold $20.18M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $211,694 was made by Dhingra Ankur (Chief Financial Officer) on 2021‑11‑24.
List of Insider Buy and Sell Transactions, CareDx, Inc
| 2025-05-12 | Sale | COURNOYER CHRISTINE | director | 29,136 0.051% | $15.96 | $465,022 | +0.37% | |
| 2025-05-06 | Sale | COURNOYER CHRISTINE | director | 16,700 0.0299% | $14.13 | $235,929 | +7.84% | |
| 2025-05-05 | Sale | Novack Jeffrey Adam | Secretary and General Counsel | 2,688 0.0047% | $14.70 | $39,514 | +1.98% | |
| 2025-04-30 | Sale | Maag Peter | director | 13,281 0.0245% | $17.23 | $228,796 | -10.01% | |
| 2025-04-07 | Sale | Jain Abhishek | Chief Financial Officer | 265 0.0005% | $17.72 | $4,696 | -1.21% | |
| 2025-04-07 | Sale | Novack Jeffrey Adam | Secretary and General Counsel | 924 0.0017% | $17.72 | $16,373 | -1.21% | |
| 2025-03-10 | Sale | Bickerstaff George | director | 20,000 0.0366% | $18.36 | $367,102 | -0.91% | |
| 2025-02-04 | Sale | Novack Jeffrey Adam | Secretary and General Counsel | 3,512 0.0065% | $23.30 | $81,829 | -19.00% | |
| 2024-12-04 | Sale | Novack Jeffrey Adam | Secretary and General Counsel | 1,917 0.0036% | $26.00 | $49,842 | -19.41% | |
| 2024-11-26 | Sale | Maag Peter | director | 5,000 0.0093% | $25.00 | $125,000 | -16.10% | |
| 2024-11-25 | Sale | Novack Jeffrey Adam | Secretary and General Counsel | 1,223 0.0023% | $24.00 | $29,352 | -12.53% | |
| 2024-11-18 | Sale | Novack Jeffrey Adam | Secretary and General Counsel | 5,534 0.0104% | $21.77 | $120,477 | -1.88% | |
| 2024-08-21 | Sale | Johnson Alexander L | See Remarks | 21,557 0.0399% | $32.58 | $702,327 | -31.80% | |
| 2024-08-20 | Sale | Maag Peter | director | 35,552 0.0686% | $33.04 | $1.17M | -29.80% | |
| 2024-08-20 | Sale | Johnson Alexander L | See Remarks | 39,466 0.0765% | $33.17 | $1.31M | -29.80% | |
| 2024-08-19 | Sale | Johnson Alexander L | See Remarks | 34,231 0.0641% | $33.55 | $1.15M | -32.94% | |
| 2023-10-02 | Sale | Seeto Reginald | See Remarks | 2,818 0.0052% | $6.91 | $19,483 | +58.67% | |
| 2023-09-05 | Sale | Seeto Reginald | See Remarks | 2,819 0.0054% | $9.49 | $26,762 | +8.86% | |
| 2023-08-14 | Sale | Seeto Reginald | See Remarks | 576 0.001% | $8.89 | $5,123 | +4.65% | |
| 2023-08-02 | Sale | Seeto Reginald | See Remarks | 2,819 0.0053% | $11.35 | $31,988 | -13.59% |
Insider Historical Profitability
| Jain Abhishek | Chief Financial Officer | 337418 0.606% | $5.41M | 0 | 1 | |
| Maag Peter | director | 316743 0.5689% | $5.07M | 4 | 56 | +57.09% |
| Johnson Alexander L | See Remarks | 284983 0.5118% | $4.57M | 0 | 3 | |
| Novack Jeffrey Adam | Secretary and General Counsel | 121350 0.2179% | $1.94M | 0 | 6 | |
| Bickerstaff George | director | 103027 0.185% | $1.65M | 0 | 6 | |
| COURNOYER CHRISTINE | director | 37045 0.0665% | $593,460.90 | 0 | 2 | |
| TPG Group Holdings (SBS) Advisors, Inc. | 10 percent owner | 1075090 1.9308% | $17.22M | 1 | 0 | <0.0001% |
| BYERS BROOK H | 751174 1.3491% | $12.03M | 1 | 0 | <0.0001% | |
| KLEINER PERKINS CAUFIELD & BYERS X A LP | 10 percent owner | 751174 1.3491% | $12.03M | 1 | 0 | <0.0001% |
| Seeto Reginald | See Remarks | 479164 0.8606% | $7.68M | 0 | 34 | |
| Gagnon Neil | 10 percent owner | 107940 0.1939% | $1.73M | 48 | 1 | +71.45% |
| Bell Michael Brian | Chief Financial Officer | 103343 0.1856% | $1.66M | 1 | 10 | +288.89% |
| Nelles Mitchell J | Chief Operating Officer | 85160 0.1529% | $1.36M | 1 | 2 | <0.0001% |
| Goldberg Michael | 62267 0.1118% | $997,517.34 | 1 | 12 | <0.0001% | |
| SNYDERMAN RALPH | director | 51015 0.0916% | $817,260.30 | 0 | 5 | |
| Yee James P | Chief Medical Officer | 42045 0.0755% | $673,560.90 | 0 | 5 | |
| King Sasha | Chief Marketing Officer | 40139 0.0721% | $643,026.78 | 0 | 16 | |
| HAGSTROM WILLIAM A | director | 18575 0.0334% | $297,571.50 | 0 | 6 | |
| Whitson Todd | Chief Commercial Officer | 10000 0.018% | $160,200.00 | 1 | 0 | <0.0001% |
| LUDLUM KEN | Chief Financial officer | 5000 0.009% | $80,100.00 | 1 | 0 | <0.0001% |
| Dhingra Ankur | Chief Financial Officer | 5000 0.009% | $80,100.00 | 1 | 0 | <0.0001% |
| Colon Grace | 4864 0.0087% | $77,921.28 | 0 | 3 | ||
| TORRES ARTHUR A | director | 2855 0.0051% | $45,737.10 | 1 | 0 | <0.0001% |
CDNA Institutional Investors: Active Positions
| Increased Positions | 127 | +56.7% | 8M | +16.43% |
| Decreased Positions | 95 | -42.41% | 6M | -12.07% |
| New Positions | 42 | New | 3M | New |
| Sold Out Positions | 34 | Sold Out | 1M | Sold Out |
| Total Postitions | 256 | +14.29% | 54M | +4.36% |
CDNA Ownership Change vs Market
Institutional Investor Ownership
| Blackrock, Inc. | $76,114.00 | 9.06% | 5.07M | -11,469 | -0.23% | 2025-03-31 |
| Vanguard Group Inc | $72,896.00 | 8.68% | 4.86M | +323,554 | +7.13% | 2024-12-31 |
| State Street Corp | $39,886.00 | 4.75% | 2.66M | +623,010 | +30.6% | 2024-12-31 |
| Ark Investment Management Llc | $36,137.00 | 4.3% | 2.41M | -579,497 | -19.39% | 2024-12-31 |
| Bamco Inc /Ny/ | $33,109.00 | 3.94% | 2.21M | +330,627 | +17.62% | 2024-12-31 |
| Fred Alger Management, Llc | $24,210.00 | 2.88% | 1.61M | +110,471 | +7.35% | 2024-12-31 |
| Invesco Ltd. | $22,723.00 | 2.71% | 1.51M | +51,160 | +3.5% | 2024-12-31 |
| Nikko Asset Management Americas, Inc. | $22,470.00 | 2.68% | 1.5M | -154,741 | -9.36% | 2024-12-31 |
| Renaissance Technologies Llc | $21,483.00 | 2.56% | 1.43M | +196,298 | +15.88% | 2024-12-31 |
| Gagnon Securities Llc | $21,468.00 | 2.56% | 1.43M | -6,526 | -0.45% | 2024-12-31 |